{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ocular+Tumor&page=8", "query": { "condition": "Ocular Tumor", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 618, "total_pages": 62, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ocular+Tumor&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ocular+Tumor&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T10:42:35.972Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02194452", "title": "Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acoustic Schwannoma", "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Meningioma", "Adult Anaplastic Oligodendroglioma", "Adult Brain Stem Glioma", "Adult Choroid Plexus Tumor", "Adult Craniopharyngioma", "Adult Diffuse Astrocytoma", "Adult Ependymoblastoma", "Adult Ependymoma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Grade I Meningioma", "Adult Grade II Meningioma", "Adult Medulloblastoma", "Adult Meningeal Hemangiopericytoma", "Adult Mixed Glioma", "Adult Myxopapillary Ependymoma", "Adult Oligodendroglioma", "Adult Papillary Meningioma", "Adult Pilocytic Astrocytoma", "Adult Pineal Gland Astrocytoma", "Adult Pineoblastoma", "Adult Pineocytoma", "Adult Subependymal Giant Cell Astrocytoma", "Adult Subependymoma", "Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebellar Astrocytoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebellar Astrocytoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Medulloepithelioma", "Childhood Supratentorial Ependymoma", "Meningeal Melanocytoma", "Newly Diagnosed Childhood Ependymoma", "Recurrent Adult Brain Tumor", "Recurrent Childhood Anaplastic Astrocytoma", "Recurrent Childhood Anaplastic Oligoastrocytoma", "Recurrent Childhood Anaplastic Oligodendroglioma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Diffuse Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Fibrillary Astrocytoma", "Recurrent Childhood Gemistocytic Astrocytoma", "Recurrent Childhood Giant Cell Glioblastoma", "Recurrent Childhood Glioblastoma", "Recurrent Childhood Gliomatosis Cerebri", "Recurrent Childhood Gliosarcoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Oligoastrocytoma", "Recurrent Childhood Oligodendroglioma", "Recurrent Childhood Pilocytic Astrocytoma", "Recurrent Childhood Pilomyxoid Astrocytoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Pleomorphic Xanthoastrocytoma", "Recurrent Childhood Protoplasmic Astrocytoma", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Recurrent Childhood Visual Pathway Glioma", "Untreated Childhood Anaplastic Astrocytoma", "Untreated Childhood Anaplastic Oligodendroglioma", "Untreated Childhood Brain Stem Glioma", "Untreated Childhood Cerebellar Astrocytoma", "Untreated Childhood Cerebral Astrocytoma", "Untreated Childhood Diffuse Astrocytoma", "Untreated Childhood Fibrillary Astrocytoma", "Untreated Childhood Gemistocytic Astrocytoma", "Untreated Childhood Giant Cell Glioblastoma", "Untreated Childhood Glioblastoma", "Untreated Childhood Gliomatosis Cerebri", "Untreated Childhood Gliosarcoma", "Untreated Childhood Medulloblastoma", "Untreated Childhood Oligoastrocytoma", "Untreated Childhood Oligodendroglioma", "Untreated Childhood Pilocytic Astrocytoma", "Untreated Childhood Pilomyxoid Astrocytoma", "Untreated Childhood Pineoblastoma", "Untreated Childhood Pleomorphic Xanthoastrocytoma", "Untreated Childhood Protoplasmic Astrocytoma", "Untreated Childhood Subependymal Giant Cell Astrocytoma", "Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor", "Untreated Childhood Visual Pathway and Hypothalamic Glioma", "Untreated Childhood Visual Pathway Glioma" ], "interventions": [ { "name": "gallium Ga 68-edotreotide", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "computed tomography", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Sue O'Dorisio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "29 Years", "sex": "ALL", "summary": "6 Months to 29 Years" }, "enrollment_count": 0, "start_date": "2013-09", "completion_date": "2017-03", "has_results": false, "last_update_posted_date": "2017-04-28", "last_synced_at": "2026-10-12T10:42:35.972Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02194452" }, { "nct_id": "NCT04364230", "title": "Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Ocular Melanoma", "Uveal Melanoma" ], "interventions": [ { "name": "6MHP", "type": "DRUG" }, { "name": "NeoAg-mBRAF", "type": "DRUG" }, { "name": "PolyICLC", "type": "DRUG" }, { "name": "CDX-1140", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2020-09-28", "completion_date": "2024-03-14", "has_results": false, "last_update_posted_date": "2024-07-16", "last_synced_at": "2026-10-12T10:42:35.972Z", "location_count": 2, "location_summary": "Cleveland, Ohio • Charlottesville, Virginia", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04364230" }, { "nct_id": "NCT05341349", "title": "Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Melanoma of Unknown Primary", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Metastatic Mucosal Melanoma", "Metastatic Ocular Melanoma", "Pathologic Stage IV Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Tumor Treating Fields Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "PROCEDURE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 1, "start_date": "2022-10-13", "completion_date": "2024-05-31", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-12T10:42:35.972Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05341349" }, { "nct_id": "NCT05075993", "title": "Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Esophageal", "Gastric Cancer", "Metastatic Head and Neck Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic HPV Related Solid Tumors", "Metastatic Ovarian Carcinoma", "Metastatic Soft Tissue Sarcoma", "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "LVGN3616 + LVGN6051 + Nab-Paclitaxel", "type": "DRUG" }, { "name": "LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide", "type": "DRUG" }, { "name": "LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel", "type": "DRUG" }, { "name": "LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 352, "start_date": "2021-11-12", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-12T10:42:35.972Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05075993" }, { "nct_id": "NCT01430416", "title": "Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "AEB071", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2011-12-20", "completion_date": "2019-05-22", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-10-12T10:42:35.972Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01430416" }, { "nct_id": "NCT00031733", "title": "Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)" ], "interventions": [ { "name": "MART-1 antigen", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "tyrosinase peptide", "type": "BIOLOGICAL" }, { "name": "alum adjuvant", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2002-02", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-10-12T10:42:35.972Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031733" }, { "nct_id": "NCT00006225", "title": "Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "recombinant flt3 ligand", "type": "BIOLOGICAL" }, { "name": "recombinant human thrombopoietin", "type": "BIOLOGICAL" }, { "name": "recombinant interleukin-3", "type": "BIOLOGICAL" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": null, "start_date": "1999-11", "completion_date": "2004-01", "has_results": false, "last_update_posted_date": "2012-06-06", "last_synced_at": "2026-10-12T10:42:35.972Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006225" }, { "nct_id": "NCT01417520", "title": "Clinical and Pathophysiological Investigations Into Erdheim Chester Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myelofibrosis", "Gaucher Disease", "Pulmonary Fibrosis", "Hermansky-Pudlak Syndrome (HPS)", "Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "National Human Genome Research Institute (NHGRI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "2 Years to 80 Years" }, "enrollment_count": 88, "start_date": "2011-08-01", "completion_date": "2019-07-24", "has_results": false, "last_update_posted_date": "2019-07-26", "last_synced_at": "2026-10-12T10:42:35.972Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01417520" }, { "nct_id": "NCT00237185", "title": "A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)" ], "interventions": [ { "name": "Imatinib mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2000-06", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2014-08-19", "last_synced_at": "2026-10-12T10:42:35.972Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Portland, Oregon • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00237185" }, { "nct_id": "NCT00109005", "title": "Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Revlimid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2005-04", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2017-01-02", "last_synced_at": "2026-10-12T10:42:35.972Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00109005" } ] }